NCT Number: NCT03364556
Nutritional Intake and Bone Health in Celiac Disease
Celiac disease leads to malnutrition and secondary conditions including osteoporosis. The dietary habits of adults with untreated, undiagnosed celiac disease has not yet been observed, but presents a critical piece in understanding the effects of the disease on bone health. Objective was to evaluate differences in nutritional intake of calcium, vitamin D, and phosphorus; serologic indices of these nutrients; and bone health among adults with and without celiac disease. Cross-sectional data from What We Eat in America (WWEIA) and the National Health and Nutrition Examination Survey (NHANES) 2009-14 was analyzed.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
About this study
Celiac disease leads to malnutrition and secondary conditions including osteoporosis. The dietary habits of adults with untreated, undiagnosed celiac disease has not yet been observed, but presents a critical piece in understanding the effects of the disease on bone health. Objective was to evaluate differences in nutritional intake of calcium, vitamin D, and phosphorus; serologic indices of these nutrients; and bone health among adults with and without celiac disease.
Cross-sectional data from What We Eat in America (WWEIA) and the National Health and Nutrition Examination Survey (NHANES) 2009-14 was analyzed, including self-reported dietary and supplement intake from one day of 24-hour recalls, serologic indicators, and dual x-ray absorptiometry (DXA) scans were analyzed in adults (n=49) testing positive for celiac disease to the tissue transglutaminase endomysial antibody assay (tTG-EMA). Statistical analysis included multiple linear regression modelling controlled for age, sex, race/ethnicity, energy intake, and poverty income ratio.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Adults aged 18+ years with a complete 24-hour recall in WWEIA and a completed celiac disease serologic test. Two groups were used in the analysis. The control group consisted of a normal adult population without celiac disease, as indicated by a negative serologic test for celiac disease and no self-reported celiac disease. The serologically positive group were considered to have undiagnosed, untreated celiac disease based on a positive serologic test for celiac disease (EMA+), no self-reported celiac disease, and no adherence to a gluten-free diet. NHANES employs two steps of serologic tests for selected participants to screen for celiac disease antibodies that develop as a T-cell-mediated response to gluten.
Exclusion criteria
- Adults were excluded if they were pregnant or breastfeeding at the time of the study, or if they reported any history of celiac disease.
Treatment and study plan
Primary outcomes
-
Dietary Intake
Time frame: 24 hours
24 hour recall
Secondary outcomes
-
Bone Mineral Density
Time frame: Baseline
DXA
Interested in participating?
Looking for future studies?
Notify MeSponsors and collaborators
Lead sponsor
George Mason University
Other
Registry information
Official study title
Nutritional Intake and Bone Health Among Adults With Undiagnosed, Untreated Celiac Disease
Important dates
- Study start
- 2016
- Primary completion
- 2017
- Study completion
- 2017
- First posted
- Dec 6, 2017
- Registry last updated
- Dec 6, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Clinical Presentation of Celiac Disease in Last 14 Years
NCT07842848
Celiac Disease, Clinical Presentation
Cairo, Egypt
View Trial DetailsDouble Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission
NCT05636293
Celiac Disease, Digestive System Diseases
Boston, Massachusetts, United States
View Trial DetailsA Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease
NCT06587828
Ankylosing Spondylitis, Ankylosis
Orange, California, United States
View Trial DetailsEffects of A2 Dairy Consumption in Celiac Adolescents
NCT07815821
A2 β-casein-containing Milk and Dairy Products, Celiac Disease
Istanbul, Turkey (Türkiye)
View Trial Details